Dr (MD) Friederike Ufer

Dr Friederike Ufer works as a clinical researcher in the Department of Experimental Neurology at Charité – Universitätsmedizin Berlin. Her research focuses on the link between autoimmunity and neurodegeneration. Dr. Ufer is a member of the IA-PACS-CFS study team, a randomised, controlled clinical trial investigating the efficacy of immunoadsorption in ME/CFS patients. Another focus of Dr. Ufer's research is the investigation of potential therapies based on monoclonal antibodies. For example, she is involved in the ABCD study evaluating the efficacy and safety of Rituximab in patients with amyotrophic lateral sclerosis (ALS). In this context, Dr. Ufer is a co-author of an article on the role of monoclonal antibodies as a potential therapeutic approach in post-COVID syndrome and ME/CFS, published in the journal Expert Opinion on Biological Therapy.